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Abstract Azathioprine leads to changes in mean corpuscular volume (MCV) and
white blood cell (WBC) indices reflecting efficacy or toxicity. Understanding
the interactions between bone marrow stem cells and azathioprine could
highlight abnormal response patterns as forerunners for hematologic malig-
nancies. This study gives a statistical description of factors influencing the
relationship between MCV and WBC in children with inflammatory bowel
disease treated with azathioprine.We found that leukopenia preceded macro-
cytosis.Macrocytosis is therefore not a good predictor of leukopenia. Further
studies will be necessary to determine the subgroup of patients at increased
risk of malignancies based on bone marrow response.
Introduction
Azathioprine is a prodrug purine analog thought
to exert its immunosuppressive effect through re-
duction in the proliferation of immune cells by
interfering with lymphocyte DNA replication and
RNA synthesis, and via downregulation of the anti-
apoptotic protein bcl-xL leading to premature
apoptosis.[1] Increased use of azathioprine in in-
flammatory bowel disease (IBD) is a consequence
of studies confirming its effect in maintenance of
remission and reduction in episodes of disease
relapse.[2]
Serious adverse effects of azathioprine include
pancreatitis, bonemarrow suppression, sepsis, aller-
gic reactions, and drug-induced hepatitis.[3] Minor
hematologic and biochemical disturbances usu-
ally necessitate dose reduction rather than drug
discontinuation. Of more recent concern is the
long-term risks of thiopurine-mediated malig-
nancy.[4,5] It has been shown that patients with
sustained leukopenia during 6-mercaptopurine
(a metabolite of azathioprine) therapy had an in-
creased risk of hematologic malignancies compar-
ed with control patients.[6] An emerging concern
centers on the synergistic risk of malignancy in
IBD when azathioprine or 6-mercaptopurine is
combined with biologic anti-tumor necrosis fac-
tor agents.[7] Knowledge of how azathioprine in-
teracts with bone marrow stem cells over time is
necessary to understand the balance between the
benefits of disease control and reducing the risk
of future malignancy and other adverse events.
Azathioprine is known to lead to macrocytosis
and leukopenia.[8] Previous reports have looked
at these parameters independently. Fraser et al.[9]
showed that lower white blood cell (WBC) count,
lower neutrophil count, and independently higher
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mean corpuscular volume (MCV), but not lym-
phocyte count, were good predictors of achieving
and maintaining remission. Thomas et al.[10] found
that MCV could be used as a surrogate marker
for 6-thioguanine nucleotide concentration. How-
ever, their study was unable to link changes in
MCV with toxicity or to identify a significant
relationship with leukocyte counts. Glas et al.[11]
showed that lower leukocyte counts were asso-
ciated with disease remission. These findings have
not been replicated in pediatric studies. There are
no studies that have defined the temporal and
dose-response relationships in hematologic pa-
rameters in children treated with azathioprine.
In order to further understand how these pa-
rameters change in children with IBD treated
with azathioprine, this study specifically aimed to
(i) statistically describe the relationship between
MCV and differential WBC count over time in
children with IBD treated with azathioprine; and
(ii) determine the effect of age, sex, diagnosis,
azathioprine dose per kg of bodyweight, thiopu-
rine methyltransferase (TPMT) level, and addi-
tional therapy on this relationship.
Methods
Patients attending the Sheffield Children’s
Hospital (Sheffield, UK) who were prescribed
azathioprine from April 2002 to April 2007 were
identified from the hospital pharmacy database.
All patients for whom azathioprine was prescrib-
ed for a diagnosis of IBD were included. Case
notes and laboratory data were reviewed to deter-
mine patient demographics, hematologic indices,
azathioprine dosage, bodyweight, and additional
treatmentmodalities over predefined time intervals.
These time intervals were defined as T1 (baseline
values within 6 months prior to commencing
azathioprine), T2 (2–3 months after commence-
ment of azathioprine), T3 (5–6 months after com-
mencement of azathioprine), T4 (11–12 months
after commencement of azathioprine), and T5
(23–24 months after commencement of azathio-
prine). Where multiple values for laboratory re-
sults were present in the predefined time windows,
an average value was taken of those readings
qualifying for study inclusion.
Analysis was performed with Data Desk 5.0
statistical software (Description, Inc., Ithaca,
NY, USA). Non-parametric data were log trans-
formed prior to regression analysis. Comparison
of summary values was via Mann-Whitney U
test for non-parametric data and paired t-test for
parametric data (changes from baseline analysis).
Trends were tested for significance by ANOVA
and more complex interactions between hemato-
logical parameters, sex, age, TPMT, and diag-
nosis by multiple regression analysis.
Results
A total of 113 patients under 16 years of age
were identified. Sixteen patients were excluded








male 33 8 11
female 19 6 20
Age at diagnosis (y) 11.3 (3.7) 12.3 (3.0) 11.6 (2.6)
Dose of azathioprine initiated (mg/kg) 1.8 (0.7) 1.6 (0.6) 1.6 (0.7)
Dose of azathioprine at termination (mg/kg) 2.7 (0.7)* 2.2 (1.3) 2.3 (0.7)
Baseline MCV (fL) 74.7 (7.5)* 80.1 (5.4) 79.1 (6.2)
Baseline WBC (109/L) 10.7 (3.5) 11.1 (5.23) 11.7 (1.7)
TPMT level (pmol 6-MMP/hour/mgHb) 30.5 (8.2) 32.6 (5.2) 32.0 (10.1)
a Values are presented as the arithmetic mean with standard deviation in parentheses.
6-MMP =6-methylmercaptopurine;MCV =mean corpuscular volume; TPMT = thiopurine methyltransferase;WBC =white blood cell; * p < 0.05
vs other disease groups.
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from the analysis on the basis of the following pre-
defined criteria: (i) six children had incomplete or
unobtainable data for the first 3 months of com-
mencing azathioprine; (ii) seven patients were
transferred to adult services within 3 months of
commencing azathioprine; and (iii) three children
discontinued azathioprine in the first 3 months
as a consequence of adverse reactions (two with
hyperamylasemia and one with neutropenia).
Table I summarizes the patient characteristics of
the remaining 97 patients. MCV was notably
lower in the group of patients with Crohn’s dis-
ease (74.7 fL [SD 7.5] vs 79.1 fL [SD 6.2]; p < 0.05)
when compared with the second largest group,
namely indeterminate colitis. The patient num-
bers at each successive time interval, which are
presented in table II, demonstrate that the ma-
jority of patients were within 12 months of com-
mencing azathioprine therapy.
Total WBC and neutrophil count fell steadily
within the first 6months of treatment then reached
a plateau between 6 and 24 months (figure 1). The
mean values at T3–T5 were approximately 25%
lower than the values at baseline (mean minimum
total WBC count of 7.6· 109/L [SD 0.4] {p< 0.05}
occurring at 5.8 months [SD 0.2] {p< 0.05}). Con-
versely, MCV increased steadily within the first
6 months of treatment, with a plateau between 12
and 24 months (figure 2). This equates to a mean
maximumMCVof 87.9 fL (SD1.8) [p< 0.05], which
occurred at a mean time of 9.7 months (SD 2.8)
[p < 0.05], i.e. 3.9 months after WBC count pla-
teaued. This represented a mean percentage in-
crease inMCV of 15% from baseline. The plateau
occurred despite a steady increase in the cumu-
lative dose of azathioprine per kg of bodyweight
at each time interval (from 1.75mg/kg [SD 0.75]
at baseline to 2.44mg/kg [SD 0.77] at T5), as
shown in figure 3.
Ten children were macrocytic (MCV >100 fL)
at 24 months. These children were noted to have
a significantly greater MCV at baseline (80.5 fL
[SD 3.9] vs 70.5 fL [SD 4.3]; p= 0.006) than chil-
dren who had normocytic red blood cells at
24 months.
The relationship between MCV and WBC
values (or change in MCV and change in WBC)
across the study period was not influenced by
age, sex, azathioprine dose per kg of bodyweight,
concomitant infliximab use, elemental diet, or
corticosteroid use being factored into a multi-
factorial regression. Furthermore, TPMT was
noted to be a weak predictor of the relationship
between MCV and WBC (p < 0.05; r2 = 15%) in a
multifactorial regression analysis. However, the
Table II. Mean timepoint at each analysis (standard deviation given in parentheses)
Analysis period Target time interval (mo) Actual mean timepoint (mo) Total number of patients
at each interval (n)
T1 0 0 97
T2 2–3 2.55 (0.6) 97
T3 5–6 5.69 (0.8) 88
T4 11–12 11.06 (1.7) 81






























Fig. 1. Trend in differential white blood cell (WBC) count.
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association between MCV and WBC count was
significantly strengthened by including a diagno-
sis of Crohn’s disease in the regression (p < 0.05;
r2 = 17%).
Discussion
This study defines a temporal relationship be-
tween WBC count and MCV. Opinion that ele-
vated MCV could predict leukopenia secondary
to azathioprine toxicity is commonplace; how-
ever, our data do not support this notion. In fact,
since leukopenia generally precedes macrocyto-
sis, this is unlikely to be the case. We therefore
suggest that although macrocytosis may indicate
toxicity, it is less likely to be able to predict it in a
timely manner. Since the majority of the reduc-
tion in WBC, lymphocyte, and neutrophil counts
occurs in the first 6 months, it is more likely that
regular blood monitoring in the first 6 months of
azathioprine therapywill detect drug-induced bone
marrow suppression, although this can occur at
any stage of therapy.[12] Since indices stabilize by
12 months, the frequency of monitoring can be
reduced thereafter.
Our findings identified that the patients who
were macrocytic at 24 months were also noted
to have an elevated MCV at baseline. There was
no clinical evidence of toxicity in these patients. It
is possible that this group had a greater baseline
MCV due to, as yet, unidentified genetic factors
or disease-related factors such as vitamin B12 or
folate deficiency. Our study did not include assess-
ments of B12 levels or folate as potential causes of
macrocytosis. Although MCV levels reached a
plateau, they never returned to baseline, indicat-
ing a likely sustained effect of azathioprine ra-
ther than a confounding factor. If vitamin B12 or
folate deficiency were presumed to be the con-
founding factor, one would expect MCV to return
to baseline as the clinical status of the disease im-
proved. This did not occur. Therefore, it is more
likely that pretreatment factors that are, as yet,
unknown may predispose some children to a
greater degree of drug-induced macrocytosis.
It is postulated that azathioprine-induced
macrocytosis is due to inhibition of DNA synthe-
sis in bone marrow precursor cells, leaving both
RNA and protein synthesis ongoing and leading
to cellular accumulation of nucleic acids.[13] The
difference in individual toxicity may be explained
by genetic polymorphisms of the genes encod-
ing enzymes in thiopurine metabolism.[12] Fur-
ther studies will be necessary to determine if
this cohort of patients is at increased risk of
malignancies.
This study is limited by its retrospective nature









































Fig. 3. Mean dose of azathioprine against time.
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a prospective review, where each patient is moni-
tored over a full 24-month period. In this study,
through a cohort effect, there was a gradual re-
duction in subject numbers analyzed at each time
interval. A prospective review would allow assess-
ment of the Paediatric Crohn’s Disease Activity
Index, so that trends in hematologic and bio-
chemical parameters could also be correlated with
clinical response. In addition, our graphical anal-
ysis gives cumulative data, which might have
masked extremes of leukopenia andmacrocytosis.
Conclusion
Our study has identified that leukopenia gen-
erally precedes macrocytosis. Macrocytosis would
therefore not be a good indicator in predicting
onset of leukopenia. Pretreatment factors that are,
as yet, unrecognizedmay predispose some children
to drug-induced macrocytosis. This could also rep-
resent a cohort of children who are at risk of ma-
lignancies, necessitating further study.
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